Breast Cancer Treatment Stocks
Oncology-focused biotechnology and diagnostic firms in this segment develop targeted therapies, molecular screening tools, and precision imaging systems specifically engineered to address the heterogeneous nature of malignant mammary tumors.
As of Oct 23, 2026, Breast Cancer Treatment has 21 US-listed companies worth $2.1T combined. The median member moved +1.4% over the past week; OKUR led at +20.0% and YDES trailed at -16.4%.
Companies in Breast Cancer Treatment
- LLY – Eli Lilly and Company, $1.1T
- NVS – Novartis AG ADR, $287B
- AZN – AstraZeneca PLC, $266B
- GILD – Gilead Sciences Inc, $193B
- PFE – Pfizer Inc, $171B
- RLAY – Relay Therapeutics Inc, $4B
- CELC – Celcuity LLC, $3.2B
- OLMA – Olema Pharmaceuticals Inc, $684M
- PBYI – Puma Biotechnology Inc, $506M
- YDES – YD Bio Ltd, $477M
- ARVN – Arvinas Inc, $472M
- GLSI – Greenwich Lifesciences Inc, $226M
- ANIX – Anixa Biosciences Inc, $101M
- OKUR – OnKure Therapeutics, Inc., $97.6M
- ONCY – Oncolytics Biotech Inc, $71.8M
- LONA – LeonaBio, Inc., $49M
- BCTX – Briacell Therapeutics Corp, $30.1M
- ATOS – Atossa Genetics Inc, $24.3M
- PCSA – Processa Pharmaceuticals Inc, $5.1M
- ICCM – Icecure Medical, $4.9M
- EFTR – Effector Therapeutics Inc, $940